HomeNewsBusinessBuy Hika; target of Rs 500: ICICI Direct

Buy Hika; target of Rs 500: ICICI Direct

ICICI Direct is bullish on Hika has recommended buy rating on the stock with a target price of Rs 500 in its research report dated February 21, 2021.

February 21, 2022 / 19:17 IST
Story continues below Advertisement

ICICI Direct's research report on Hika

Hikal is predominantly a B2B player that provides intermediates and active ingredients to global pharmaceutical, animal health, crop protection and specialty chemical companies. Pharma and crop protection are 62% and 38% of operating revenues, respectively. The pharma business is currently divided in 50:50 ratio of APIs and CDMO. Animal health business accounts for 20-25% of CDMO business In crop protection, 69% revenues are derived from CDMO while remaining is from proprietary products, specialty chemicals & specialty biocides One of the largest suppliers of Gabapentin API (CNS) and in crop protection, one of the largest suppliers of Thiabendazole (TBZ)

Story continues below Advertisement

Outlook

Maintain BUY on account of 1) consistency in offtake for crop protection CDMO, 2) expected recovery in Pharma, 3) Visibility capex. That said we continue to monitor developments on recent critical issues- 1) Surat (Gujrat) GIDC incident and 2) MPCB notice for Taloja. Valued at Rs 500 i.e. 22x P/E on FY24E EPS of Rs 22.6